The Q1 miss is largely due to one-time IPR&D charges, but the underlying business continues to grow. The maintained full-year guidance and strong cash position support the long-term story. Traders should watch for post-earnings volatility and the upcoming pitolisant GR NDA submission in Q2 2026 as a near-term catalyst.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 7 $31.42entry
- T+1 · 6mo ago −1.37%α −2.20% · $30.99
- T+5 · 6mo ago −1.88%α −3.38% · $30.83
- T+20 · 6mo ago +2.16%α −0.97% · $32.10
- T+60 · 4mo ago +13.30%α +9.47% · $35.60
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Harmony Biosciences reported Q1 2026 revenue of $215.4M (+17% YoY), slightly below consensus of $220.8M. GAAP diluted EPS of $0.55 missed consensus of $0.93 by 41%, driven by $32M in upfront license payments. The company reaffirmed FY2026 revenue guidance of $1.0B-$1.04B, citing continued WAKIX growth and pipeline progress.
Key Financial Metrics
Key Facts
- Q1 2026 net product revenue $215.4M, +17% YoY ($184.7M)
- GAAP net income $32.5M ($0.55 diluted) vs $45.6M ($0.78) in Q1 2025
- EPS missed consensus ($0.93) by 41% due to $32M in upfront license payments ($0.45 after-tax impact)
- Reiterated FY2026 revenue guidance of $1.0B-$1.04B
- Cash, equivalents and investments of $870.5M at quarter end
- R&D expenses surged 101% to $69.4M, driven by license agreement costs
- Cost of product sold as % of revenue rose to 20.7% from 17.3% due to new royalties
- Completed settlements with 6 of 7 ANDA filers; filed patent suit against AET Pharma/Sandoz
Financial Impact
Q1 2026 revenue $215.4M (+17% YoY); GAAP EPS $0.55 vs $0.93 consensus; net income $32.5M vs $45.6M YoY
Risk Factors
- EPS miss could weigh on near-term sentiment despite explanation
- Rising cost of product sold (royalties) may pressure margins
- Execution risk on pipeline (pitolisant GR NDA, BP-205 data)
- Potential generic competition post-2030
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-056786 |
| Document: hrmy-20260507x8k.htm | 0001104659-26-056786 |
| Document: hrmy-20260507xex99d2.htm | 0001104659-26-056786 |
| Document: 0001104659-26-056786-index-headers.html | 0001104659-26-056786 |
| Document: 0001104659-26-056786-index.html | 0001104659-26-056786 |
| Document: 0001104659-26-056786.txt | 0001104659-26-056786 |
| 8-K Data (Synthetic) | 0001104659-26-056786 |
Track record
20 reports on HRMY
2 of 3 bullish or bearish reports moved the stock their way by T+20. Best: +14.82% at T+20 after the Jul 16, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $33.21 Now $32.96 −0.75% settles Dec 15
- Nov 4, 202612d ago 8-K Bearish 5/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $34.42 Now $32.96 +4.23% settles Dec 3
- Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $37.02 Now $32.96 −10.97% settles Dec 2
- Oct 30, 202617d ago 8-K/A Neutral 3/10 Entry $37.91 Now $32.96 −13.06% settles Dec 1
- Oct 27, 202620d ago SC 13G/A Neutral 2/10 Entry $38.50 Now $32.96 −14.39% settles Nov 25
- Oct 13, 20264w ago 8-K Neutral 3/10 Entry $37.03 to $33.55 Now $32.96 −10.99% ▼ −9.40% −5.79% vs SPY
- Oct 1, 20266w ago Press Release Neutral 3/10 Entry $39.57 to $38.59 Now $32.96 −16.70% ▼ −2.48% −3.18% vs SPY
- Aug 4, 202614w ago 8-K Bullish 7/10 No price data
- Aug 4, 202614w ago Press Release Bullish 6/10 Entry $38.78 Now $32.96 −15.01% No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers